ArticleJugan geon-gang gwa jilbyeong2023
[The Korean National Public-Private Mix Tuberculosis Control Project: Analysis of the Indicators for Tuberculosis Management in 2021].
Article in Jugan geon-gang gwa jilbyeong, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Tuberculosis Treatment Outcomes in the Republic of Korea, 2023].Jugan geon-gang gwa jilbyeong · 2025Article
- [Characteristics and Trends of Tuberculosis Deaths in 2023: An Analysis of Cause-of-death Statistics from Statistics Korea].Jugan geon-gang gwa jilbyeong · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Korea Disease Control and Prevention Agency has been promoting a "Public-Private Mix Tuberculosis Control Project (PPM Project)" with the "Korean Academy of Tuberculosis and Respiratory Diseases" since 2011. In 2021, 182 PPM institutions participated in the PPM Project, and managed 82.1% of tuberculosis (TB) patients. This study analyzed 35 TB management indicators based on the reported data of TB patients from 182 institutions that participated in the PPM Project in 2021. The final treatment results were confirmed through five-quarter observation by dividing the reported date by quarters. The sputum smear test rate, sputum culture test rate, and sputum MTB PCR test rate reported by PPM institutions in 2021 were 95.9%, 95.6%, and 91.5%, respectively. The rapid drug susceptibility test rate was 87.7% in 2021, an increase from 66.5% in 2020. In 2021, the rates of treatment completion within 12 months, stopped, failure, and still on treatment were 76.5%, 2.3%, 0.06%, and 7.2%, respectively. The mortality rate was 14.0%. In 2021, the household contact investigation rates in adults and children were 92.0% and 93.0%, respectively, down from 94.5% and 94.4% in 2020. On the other hand, the treatment rates for latent TB infection were 74.1% and 95.1% in adults and children, respectively, an increase from the corresponding 69.3% and 91.9% in 2020. The rates of sputum smear tests and sputum culture tests for suspected TB patient among contacts were 47.7% and 42.9%, respectively. Since more than 80% of TB patients are managed by PPM institutions, quality control of PPM institutions is important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.